Search All News
The Food and Drug Administration on Thursday overcame doubts from agency scientists and approved a fiercely debated drug for ALS
Jinsy Andrews, an associate professor in the Department of Neurology at the Vagelos College of Physicians and Surgeons, speaks about the big difference between Aduhelm and AMX0035.
A new initiative led by Columbia University and the n-Lorem Foundation will develop personalized therapies for individuals with "nano-rare" genetic forms of ALS and treat them for free, for life.
An experimental drug first tried at Columbia University Irving Medical Center as a last-ditch effort to help a 25-year-old woman with juvenile ALS is now being tested in ALS patients
- October 5, 2021
Six Columbia University scientists have received NIH High-Risk, High-Reward grants that are given to exceptionally creative scientists proposing unconventional, but potentially high-impact, research
- June 13, 2021
A public battle rages over access to experimental, trial-phase drugs
Source:BLOOMBERG NEWSApril 6, 2021
Neil Shneider, Stockman-Mauriello’s doctor and director of the Eleanor and Lou Gehrig ALS Center at Columbia University in New York, nonetheless asked Biogen for access.
Source:The Wall Street JournalSeptember 2, 2020
“Anything that can slow down the rate of decline in a disease that has no cure—or no treatment to reverse symptoms—is good,” said Jinsy Andrews.
Source:The New York TimesSeptember 2, 2020
“This is very encouraging,” said Dr. Neil Shneider, director of the Eleanor and Lou Gehrig A.L.S. Center at Columbia University, who was not involved.
Jinsy Andrews, MD, MSc, FAAN has been elected co-chair of the Northeast ALS Consortium (NEALS) for a four-year term.